Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events

Aspirin for the Primary Prevention of Cardiovascular Events

There is significant evidence that low-dose aspirin is effective in preventing the first myocardial infarction in men and ischemic stroke in women. There is also an increased risk for major gastrointestinal tract hemorrhage and a suggestive, but nonsignificant, increase in the risk for hemorrhagic stroke. If there is a history of ulcer disease or upper-gastrointestinal tract bleeding, Helicobac...

Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.

BACKGROUND To systematically review trials concerning the benefit and risk of aspirin therapy for primary prevention of cardiovascular events in patients with diabetes mellitus. METHODS We searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. Eligible studies were prospective, randomized controlled trials of aspirin therapy for primary cardiovascular prevention in p...

Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes

he burden of cardiovascular disease (CVD) among paients with diabetes is substantial. Individuals with diabetes re at twoto fourfold increased risk of cardiovascular events ompared with ageand sex-matched individuals without iabetes. In diabetic patients over the age of 65 years, 68% f deaths are from coronary heart disease (CHD) and 16% re from stroke (1). A number of mechanisms for the ncreas...

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus

Effects of changing guidelines on prescribing aspirin for primary prevention of cardiovascular events.

OBJECTIVE The use of low-dose aspirin for primary prevention of cardiovascular events in patients at elevated risk for cardiovascular disease (CVD) is increasingly being questioned. Aspirin may not benefit this population and may increase the risk of major bleeding events. Data support aspirin use in patients with known CVD. METHODS This is a secondary analysis of de-identified electronic hea...